GlassScriptPhysician profile
Richard Macneil
NPI 1376064568
$2,065.75
in general payments reported to CMS, 2019-2025
21 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $652 · 2024: $862 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $314.38 | 2023-2025 | Lokelma, Farxiga |
| Amgen INC. | $313.02 | 2024-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $291.95 | 2023-2025 | Jynarque |
| Horizon Therapeutics Plc | $151.36 | 2023 | Krystexxa |
| Travere Therapeutics, INC. | $137.54 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.52 | 2023-2024 | |
| Akebia Therapeutics INC | $116.12 | 2024-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $112.63 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $89.37 | 2023 | Oxlumo |
| Vifor Pharma, INC. | $84.07 | 2023-2024 | Veltassa |
| Calliditas Therapeutics US INC. | $63.21 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $55.02 | 2023 | Lupkynis |
| Lilly USA, LLC | $54.28 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $32.50 | 2024 | Purified Cortrophin Gel |
| Ardelyx, INC. | $23.08 | 2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.12 | 2025 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $18.98 | 2025 | Empaveli |
| Fresenius USA Marketing, INC. | $18.67 | 2025 | Velphoro |
| Opko Pharmaceuticals, LLC | $16.91 | 2025 | Rayaldee |
| Ascendis Pharma Endocrinology INC | $15.69 | 2025 | Yorvipath |
| Takeda Pharmaceuticals U.S.A., INC. | $14.33 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Macneil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.